+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Neonatal Fc receptor antagonists - Pipeline Insight, 2024

  • PDF Icon

    Drug Pipelines

  • 60 Pages
  • January 2024
  • Region: Global
  • DelveInsight
  • ID: 5504269
This “Neonatal Fc receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Neonatal Fc receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Neonatal Fc receptor antagonists Understanding

Neonatal Fc receptor antagonists: Overview

The neonatal Fc receptor (also FcRn, IgG receptor FcRn large subunit p51, or Brambell receptor) is a protein that in humans is encoded by the FCGRT gene. It is an Fc receptor which is similar in structure to the MHC class I molecule and also associates with beta-2-microglobulin. Several autoimmune disorders are caused by the binding of IgG to self antigens. Since FcRn extends IgG half-life in the circulation, it can also confer long half-lives on these pathogenic antibodies and promote autoimmune disease. Therapies seek to disrupt the IgG-FcRn interaction to increase the clearance of disease-causing IgG autoantibodies from the body. More recent approaches involve the strategy of blocking the binding of IgG to FcRn by injecting antibodies that bind with high affinity to this receptor through their Fc region or variable regions. Fc fragments or antibodies are currently being used in clinical trials as treatments for antibody-mediated autoimmune diseases such as primary immune thrombocytopenia and myasthenia gravis.

Neonatal Fc receptor antagonists - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neonatal Fc receptor antagonists pipeline landscape is provided which includes the disease overview and Neonatal Fc receptor antagonists treatment guidelines. The assessment part of the report embraces, in depth Neonatal Fc receptor antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neonatal Fc receptor antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Neonatal Fc receptor antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Neonatal Fc receptor antagonists.

Neonatal Fc receptor antagonists Emerging Drugs Chapters

This segment of the Neonatal Fc receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neonatal Fc receptor antagonists Emerging Drugs

Efgartigimod: ArgenxEfgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod binds to the neonatal Fc receptor (FcRn), which is widely expressed throughout the body and plays a central role in rescuing IgG antibodies from degradation. Blocking FcRn reduces IgG antibody levels representing a logical potential therapeutic approach for several autoimmune diseases. Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. If approved, efgartigimod will be the first-and-only approval of an FcRn antagonist, Prescription Drug User Fee Act (PDUFA) target action date is December 17, 2021. Pre-approval access program opened in U.S. for efgartigimod for eligible people living with gMG.

Neonatal Fc receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Neonatal Fc receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Neonatal Fc receptor antagonists

There are approx. 3+ key companies which are developing the therapies for Neonatal Fc receptor antagonists. The companies which have their Neonatal Fc receptor antagonists drug candidates in the most advanced stage, i.e. preregistration include Argenx.

Phases

This report covers around 3+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Neonatal Fc receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neonatal Fc receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neonatal Fc receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neonatal Fc receptor antagonists drugs.

Neonatal Fc receptor antagonists Report Insights

  • Neonatal Fc receptor antagonists Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Neonatal Fc receptor antagonists Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Neonatal Fc receptor antagonists drugs?
  • How many Neonatal Fc receptor antagonists drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neonatal Fc receptor antagonists?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neonatal Fc receptor antagonists therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Neonatal Fc receptor antagonists and their status?
  • What are the key designations that have been granted to the emerging drugs?


This product will be delivered within 2 business days.

Table of Contents

IntroductionExecutive Summary
Neonatal Fc receptor antagonists: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
  • Comparative Analysis
Efgartigimod: Argenx
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  • Comparative Analysis
Neonatal Fc receptor antagonists Key CompaniesNeonatal Fc receptor antagonists Key ProductsNeonatal Fc receptor antagonists- Unmet NeedsNeonatal Fc receptor antagonists- Market Drivers and BarriersNeonatal Fc receptor antagonists- Future Perspectives and ConclusionNeonatal Fc receptor antagonists Analyst ViewsNeonatal Fc receptor antagonists Key CompaniesAppendix
List of Tables
Table 1 Total Products for Neonatal Fc receptor antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Neonatal Fc receptor antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Argenx
  • HanAll Biopharma
  • UCB Biopharma
  • Janssen Pharmaceutical